Every legal medical cannabis market on the planet has standards that products must meet before they can be sold to patients. Products intended for European Union markets must comply with EU good manufacturing practice (GMP) standards, which are some of the most stringent standards in the emerging international cannabis industry.

Legal European Union markets, particularly Germany’s medical cannabis market, are now top targets for cannabis exports from other parts of the world. Regardless of where products originate, they must be GMP-compliant to be sold in EU markets such as Germany. GMP standards for medical cannabis products include the following, per the European Medicines Agency:

• are of consistent high quality;
• are appropriate for their intended use;
• meet the requirements of the marketing authorisation or clinical trial authorisation.

Decontamination processes are at the heart of European GMP cannabis compliance. A team of expert panelists recently discussed various approaches to cannabis decontamination, regulatory requirements, and the unique GMP compliance hurdles facing the emerging legal cannabis industry at the International Cannabis Business Conference in Berlin. The panel was moderated by Atiyyah Ferouz, Founder and CEO of AG Cann. Ms. Ferouz was joined on the panel by:

• Dr. David Surjo, CEO of GOC Nexus GmbH and CURANAT UG
• Brian Casey, Chief Revenue Officer of VIST Labs and Managing Partner of BASM Holdings
• George Terry, Executive Vice President of Rad Source
• Joseph Edwards, Chief Scientist and Vice President of Yofumo Technologies
• Arthur de Cordova, CEO and Co-Founder of Ziel

You can view the panel in its entirety at this link here.